Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has voluntarily disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 56.7B with a pharmaceutical company based in Europe.
📊 [Key Disclosure Details & Financial Figures]
- Contract Category & Details: Other Sales and Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 56,680,164,000 (USD 38,370,000)
- Applied Exchange Rate: USD/KRW 1,477.20 (Initial base rate on December 19, 2025)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on 2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 1.25%
- Counterparty: Pharmaceutical company based in Europe (Counterparty name undisclosed due to business confidentiality)
- Contract Period: December 19, 2025 – December 31, 2030
- Contract Date: December 19, 2025
- Other Important Matters:
- The contract end date is subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure on December 31, 2030, due to business confidentiality, subject to future changes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Revenue and Earnings Recognition Over Contract Period
This disclosure was published as a voluntary filing for a contract manufacturing agreement representing 1.25% of recent annual revenue.
Monitoring how revenues and earnings from this contract are recognized over the contract period (December 19, 2025 – December 31, 2030) is crucial for understanding its financial impact.
Relevant progress can be verified in upcoming periodic reports and relevant follow-up disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
